Etidronate for arterial calcification due to deficiency of CD73 (ACDC): a step in the right direction

Abstract Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic calcification disorder. Recently, a pilot study was conducted which utilized etidronate, a bisphosphonate, to treat ACDC. The results of this study indicated a significant effect on slowing arterial calcification and disease progression in a cohort of affected individuals, thereby favoring the use of etidronate as a potential treatment option for this disease. This would mark etidronate to possibly become the first standard treatment for this rare, vascular disorder. Although further research is needed to prove its efficacy, this landmark study symbolizes a step in the right direction and underscores the need for continued investigation.